Preimplantation Genetic Testing Market Size, Share, Growth, and Industry Analysis, By Types (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), By Applications (Maternity Centers & Fertility Clinics, Hospitals, Diagnostic Labs, and Service Providers, Research Laboratories & Academic Institutes ) , and Regional Insights and Forecast to 2034

Preimplantation Genetic Testing Market Size

The Global Preimplantation Genetic Testing Market size was USD 346.1 Million in 2024 and is projected to reach USD 366.17 Million in 2025, USD 387.41 Million in 2026, and expand further to USD 608.22 Million by 2034, exhibiting a steady growth rate of 5.8% during the forecast period (2025–2034). Approximately 42% of this growth is attributed to the increasing adoption of advanced embryo screening technologies, while 36% results from higher IVF cycle volumes worldwide. Over 28% of global fertility clinics have integrated next-generation sequencing for preimplantation testing applications, contributing significantly to this market expansion.

The US Preimplantation Genetic Testing Market is experiencing remarkable momentum with over 31% of total global share in 2025. Nearly 64% of American IVF centers are now utilizing PGT-A screening for embryo evaluation. Moreover, approximately 47% of couples undergoing assisted reproduction opt for genetic testing to reduce chromosomal abnormality risks. With rising fertility treatment acceptance and advanced genetic lab infrastructure, the US market remains a leading force driving innovation and precision screening adoption in the reproductive healthcare segment.

Key Findings

• Market Size: The market reached USD 346.1 Million in 2024, USD 366.17 Million in 2025, and is projected at USD 608.22 Million by 2034 with 5.8% growth.
• Growth Drivers: Around 52% rise in IVF treatments and 39% increase in genetic disorder awareness boost adoption of embryo screening technologies.
• Trends: Nearly 42% share held by NGS-based testing, while 31% growth observed in non-invasive testing technologies and AI-driven embryo evaluation.
• Key Players: Illumina, Thermo Fisher, Agilent Technologies, Coopersurgical, Natera & more.
• Regional Insights: North America leads the Preimplantation Genetic Testing Market with 39.8% share driven by advanced IVF infrastructure. Europe follows at 30.1% with strong clinical regulations. Asia-Pacific holds 24.0% fueled by fertility tourism and awareness. Middle East & Africa accounts for 6.1%, showing steady growth through healthcare investments and expanding fertility centers.
• Challenges: High testing costs (47%) and limited insurance coverage (31%) restrict widespread adoption, while 22% of regions face ethical regulation challenges.
• Industry Impact: Around 68% of fertility centers globally now use genetic testing; 37% of IVF cycles show improved success due to PGT adoption.
• Recent Developments: Over 25% of major players launched AI-integrated PGT systems, and 33% enhanced reagent efficiency, improving accuracy by up to 18% in 2024.

The Preimplantation Genetic Testing Market represents one of the fastest-evolving sectors within reproductive medicine. Nearly 66% of global IVF treatments now include genetic screening components to improve embryo selection accuracy. With strong demand from fertility clinics, rising female age demographics, and technological upgrades in NGS and AI, the market is expanding rapidly. Around 40% of global R&D investments target embryo genomics and sequencing innovation, indicating a robust pipeline of diagnostic advancements and future market scalability across emerging economies.

Preimplantation Genetic Testing Market Trends

The Preimplantation Genetic Testing Market is rapidly evolving with technological advancements and growing acceptance of fertility treatments across the globe. Nearly 42% of the market share is dominated by Next-Generation Sequencing (NGS) due to its high accuracy and efficiency in detecting chromosomal abnormalities. Around 31% of fertility clinics globally now integrate Artificial Intelligence (AI) for embryo selection, significantly improving IVF success rates. The adoption of Non-Invasive Preimplantation Genetic Testing (niPGT) has grown by 26%, reflecting the trend toward safer diagnostic methods. Additionally, about 65% of IVF cycles incorporate preimplantation testing to enhance genetic accuracy and reduce inherited disorder risks. North America contributes approximately 39.8% of the global market share, followed by Europe at 30.1%, highlighting strong regional dominance in technologically advanced regions. The Asia-Pacific region is emerging quickly, holding nearly 24% share, driven by rising fertility tourism and improved affordability of genetic screening. Furthermore, consumables and reagents account for nearly 61% of total market demand, supported by increased frequency of testing cycles and recurring laboratory needs, demonstrating the market’s dynamic and expanding nature.

Preimplantation Genetic Testing Market Dynamics

OPPORTUNITY

Expansion in Fertility Clinics and ART Centers

The preimplantation genetic testing market is witnessing significant opportunities with the expansion of Assisted Reproductive Technology (ART) centers worldwide. Around 68% of fertility clinics are now integrating genetic testing into IVF procedures. The Asia-Pacific region alone shows over 15% yearly rise in ART facility openings, with nearly 40% of new clinics adopting PGT technology. Increasing patient awareness, combined with advanced genetic diagnostics, presents massive untapped potential, especially across developing economies where fertility services are expanding rapidly.

DRIVERS

Rising Demand for Chromosomal Abnormality Screening

Increasing genetic disorder prevalence is a strong market driver. Nearly 1 in 30 infants globally are affected by congenital defects, creating growing awareness of preimplantation genetic testing benefits. PGT-A (Aneuploidy Testing) holds about 28% of total testing applications, while NGS-based technologies dominate with around 42% market share. Furthermore, fertility clinics contribute nearly 65% of the service demand, showcasing how clinic-led screening adoption is propelling market expansion across regions.

RESTRAINTS

"High Cost and Limited Accessibility"

High procedural cost and limited insurance coverage act as restraints on preimplantation genetic testing adoption. Approximately 47% of potential IVF patients in emerging economies cite affordability as the main barrier to testing. Moreover, the consumables segment represents over 60% of total market cost structure, highlighting dependency on expensive reagents. In several low-income regions, only 25–30% of clinics currently offer genetic testing, limiting its overall reach and accessibility to a wider patient base.

CHALLENGE

"Ethical Concerns and Regulatory Variations"

Ethical and regulatory challenges remain key obstacles for preimplantation genetic testing market growth. Around 35% of fertility specialists report delays due to complex ethical approvals and region-specific embryo laws. Differences in guidelines regarding embryo biopsy and genetic selection reduce international standardization. Additionally, non-invasive PGT methods currently account for less than 10% of total testing procedures, indicating the technological gap that continues to challenge market adoption and uniformity across clinical applications.

Segmentation Analysis

The Global Preimplantation Genetic Testing Market was valued at USD 346.1 Million in 2024 and is projected to reach USD 366.17 Million in 2025, expanding further to USD 608.22 Million by 2034 at a CAGR of 5.8% during 2025–2034. The market segmentation by type and application reveals strong dominance from genetic screening and fertility clinic-based applications. Among types, Preimplantation Genetic Screening (PGS) captured the majority market share due to its widespread clinical adoption and technological accuracy, while Preimplantation Genetic Diagnosis (PGD) followed with a growing presence in hereditary disease prevention. By application, Maternity Centers & Fertility Clinics lead with the highest share, followed by hospitals, diagnostic labs, and research institutions contributing to specialized testing demand.

By Type

Preimplantation Genetic Screening (PGS)

Preimplantation Genetic Screening dominates the market owing to its extensive use in embryo chromosomal abnormality detection and higher implantation success rates. Around 62% of total PGT cycles globally utilize PGS for identifying aneuploidy and improving IVF outcomes. Technological integration of next-generation sequencing and AI-based embryo selection further accelerates segment expansion.

Preimplantation Genetic Screening held the largest share in the global market, accounting for USD 210.18 Million in 2025, representing 57.4% of the total market. This segment is expected to grow at a CAGR of 6.1% from 2025 to 2034, driven by enhanced clinical accuracy, growing IVF cycles, and advanced sequencing technologies.

Top 3 Major Dominant Countries in the Preimplantation Genetic Screening (PGS) Segment

• United States led the Preimplantation Genetic Screening segment with a market size of USD 68.12 Million in 2025, holding a 32.4% share, and is expected to grow at a CAGR of 6.3% due to widespread IVF access and technological advancements.
• China followed with USD 41.76 Million in 2025, capturing a 19.9% share, driven by rising infertility rates and government-backed fertility programs.
• Japan ranked third with USD 23.65 Million in 2025, holding a 11.2% share, attributed to rapid clinical adoption and population aging factors.

Preimplantation Genetic Diagnosis (PGD)

Preimplantation Genetic Diagnosis focuses on identifying single-gene disorders, structural chromosomal rearrangements, and inherited diseases prior to embryo implantation. PGD is crucial in preventing transmission of genetic disorders like cystic fibrosis and thalassemia, with increasing use among couples with known genetic risks. Approximately 38% of total preimplantation testing demand originates from PGD.

Preimplantation Genetic Diagnosis accounted for USD 155.99 Million in 2025, representing 42.6% of the total market. This segment is forecasted to expand at a CAGR of 5.4% from 2025 to 2034, propelled by the rising burden of hereditary conditions and improved access to genetic counseling.

Top 3 Major Dominant Countries in the Preimplantation Genetic Diagnosis (PGD) Segment

• United Kingdom led the PGD segment with a market size of USD 32.11 Million in 2025, holding a 20.6% share and growing at a CAGR of 5.7% due to favorable regulatory guidelines and high clinical expertise.
• Germany followed with USD 28.74 Million in 2025, capturing a 18.4% share driven by strong genomic research infrastructure and advanced fertility care.
• India ranked third with USD 19.88 Million in 2025, holding a 12.7% share fueled by cost-effective treatment and increased IVF awareness.

By Application

Maternity Centers & Fertility Clinics

Maternity centers and fertility clinics represent the largest application segment in the global market. Over 67% of global preimplantation testing services are conducted through fertility clinics due to direct patient engagement and established ART protocols. Increasing IVF cycles and personalized reproductive medicine adoption amplify their contribution.

Maternity Centers & Fertility Clinics held the largest share, accounting for USD 243.34 Million in 2025, representing 66.5% of the total market. The segment is projected to grow at a CAGR of 6.2% through 2034, supported by growing clinic networks and reproductive health awareness.

Top 3 Major Dominant Countries in the Maternity Centers & Fertility Clinics Segment

• United States led with USD 79.61 Million in 2025, holding a 32.7% share and expected to grow at a CAGR of 6.4% due to high IVF cycles and adoption of PGS technologies.
• India followed with USD 45.73 Million, representing a 18.8% share driven by cost-effective fertility treatments.
• China ranked third with USD 33.52 Million, capturing a 13.7% share, supported by expanding ART infrastructure.

Hospitals, Diagnostic Labs, and Service Providers

Hospitals and diagnostic labs play a vital role in providing preimplantation genetic testing support services, focusing on advanced genetic screening, embryo analysis, and patient diagnostics. They are essential in bridging fertility treatment and laboratory testing integration.

This segment recorded USD 84.22 Million in 2025, accounting for 23% of total market share and growing at a CAGR of 5.6% through 2034, driven by adoption of precision medicine and hospital-based genetic testing programs.

Top 3 Major Dominant Countries in the Hospitals, Diagnostic Labs, and Service Providers Segment

• Germany led with USD 22.98 Million in 2025, holding a 27.3% share due to its strong diagnostic network and healthcare infrastructure.
• France followed with USD 18.17 Million, representing a 21.6% share driven by advanced testing capabilities.
• Japan ranked third with USD 14.65 Million, holding a 17.4% share due to increasing hospital-based ART programs.

Research Laboratories & Academic Institutes

Research laboratories and academic institutes focus on developing new genetic testing protocols and innovations in embryo genomics. These entities drive collaboration with biotech companies to enhance detection accuracy and embryo selection efficiency.

This segment achieved USD 38.61 Million in 2025, representing 10.5% of total market share, expanding at a CAGR of 5.1% through 2034 due to continuous R&D investment and genomic innovation.

Top 3 Major Dominant Countries in the Research Laboratories & Academic Institutes Segment

• United States led with USD 12.76 Million in 2025, holding a 33% share and expected to grow at a CAGR of 5.3% due to academic-biotech collaboration.
• South Korea followed with USD 8.24 Million, representing 21.3% share supported by robust R&D funding.
• United Kingdom ranked third with USD 6.55 Million, capturing 16.9% share due to strong government research support.

Preimplantation Genetic Testing Market Regional Outlook

The Global Preimplantation Genetic Testing Market, valued at USD 346.1 Million in 2024, is projected to reach USD 366.17 Million in 2025 and expand to USD 608.22 Million by 2034 at a CAGR of 5.8%. Regional analysis reveals that North America dominates with the largest share due to technological innovation, followed by Europe, which holds strong regulatory support for IVF treatments. The Asia-Pacific region is witnessing the fastest growth driven by fertility tourism and ART affordability, while the Middle East & Africa is gradually expanding due to increased healthcare investments. The total market share distribution across regions sums up to 100%, showcasing a globally balanced yet innovation-driven growth pattern.

North America

North America leads the global market owing to high awareness of genetic disorders, strong IVF infrastructure, and increasing adoption of next-generation sequencing technologies. The United States contributes significantly, supported by well-established fertility clinics and advanced healthcare funding. Around 65% of clinics in this region offer integrated PGT services, ensuring wider accessibility and precision outcomes in embryo screening.

North America held the largest share in the global preimplantation genetic testing market, accounting for USD 145.54 Million in 2025, representing 39.8% of the total market. This region is projected to grow at a CAGR of 6.0% from 2025 to 2034, driven by rising infertility rates, increasing use of AI-assisted embryo analysis, and advanced genetic diagnostics.

North America - Major Dominant Countries in the Market

• United States led the North America region with a market size of USD 96.83 Million in 2025, holding a 26.4% share, and is expected to grow at a CAGR of 6.2% due to technological leadership and high IVF volume.
• Canada followed with USD 32.65 Million in 2025, representing an 8.9% share, driven by expanded ART reimbursement policies.
• Mexico ranked third with USD 16.06 Million, holding a 4.5% share, supported by growth in fertility tourism and affordable ART treatments.

Europe

Europe is the second-largest market, driven by favorable regulatory frameworks and wide access to fertility care services. The region’s market benefits from government-backed genetic health programs and early adoption of PGT technologies. Countries such as Germany, the UK, and France dominate due to high demand for preimplantation diagnosis to prevent genetic disorders and improve pregnancy success rates.

Europe accounted for USD 110.41 Million in 2025, representing 30.1% of the global market. The region is forecasted to grow at a CAGR of 5.5% during 2025–2034, supported by rising infertility cases, ethical acceptance of embryo testing, and cross-border reproductive treatments.

Europe - Major Dominant Countries in the Market

• Germany led the European market with USD 34.87 Million in 2025, holding a 9.5% share, driven by strong clinical infrastructure and advanced genetics research.
• United Kingdom followed with USD 29.74 Million, representing an 8.1% share, supported by government-regulated IVF programs.
• France ranked third with USD 22.16 Million, accounting for a 6.0% share, attributed to high adoption of PGT-A testing and improved healthcare facilities.

Asia-Pacific

Asia-Pacific is the fastest-growing region in the preimplantation genetic testing market, propelled by rapid technological advancement, expanding fertility tourism, and increasing patient affordability. Fertility centers across China, India, Japan, and South Korea are adopting PGT at record rates. The region benefits from cost-effective IVF treatments and increasing awareness of genetic screening among reproductive-age couples.

Asia-Pacific represented USD 87.88 Million in 2025, accounting for 24.0% of the total market. The region is expected to grow at a CAGR of 6.6% through 2034, driven by growing middle-class income, supportive government fertility policies, and expansion of high-end IVF laboratories.

Asia-Pacific - Major Dominant Countries in the Market

• China led the Asia-Pacific region with USD 31.22 Million in 2025, holding an 8.5% share, supported by high IVF patient volume and rapid PGT adoption.
• India followed with USD 26.34 Million, representing a 7.2% share, driven by medical tourism and low-cost fertility treatments.
• Japan ranked third with USD 18.76 Million, capturing a 5.1% share, owing to an aging population and supportive ART initiatives.

Middle East & Africa

The Middle East & Africa market is in a developing phase but shows promising growth prospects due to increasing fertility awareness, healthcare investments, and the expansion of specialized reproductive centers. Countries like the UAE, Saudi Arabia, and South Africa are leading regional adoption through strategic public-private partnerships and advanced ART infrastructure establishment.

The Middle East & Africa region accounted for USD 22.34 Million in 2025, representing 6.1% of the total market. The region is projected to grow at a CAGR of 5.3% during 2025–2034, supported by rising fertility service penetration and improvements in healthcare accessibility.

Middle East & Africa - Major Dominant Countries in the Market

• United Arab Emirates led the Middle East & Africa region with USD 7.65 Million in 2025, holding a 2.1% share, driven by fertility tourism and high-end medical facilities.
• Saudi Arabia followed with USD 6.34 Million, representing a 1.7% share, fueled by government healthcare expansion plans.
• South Africa ranked third with USD 4.22 Million, capturing a 1.2% share, due to growing urban fertility demand and private IVF clinics’ expansion.

List of Key Preimplantation Genetic Testing Market Companies Profiled

Investment Analysis and Opportunities in Preimplantation Genetic Testing Market

The preimplantation genetic testing market presents expanding investment opportunities driven by technological innovation, fertility awareness, and genetic research integration. Around 54% of investors are focusing on advanced sequencing tools and AI-based embryo analytics. Fertility clinic investments have grown by over 32% globally, particularly in Asia-Pacific and North America. Additionally, more than 48% of new funding is directed toward consumables and reagents manufacturing, a segment that contributes 61% of recurring revenue potential. Investments in automation and data-driven embryo assessment tools are accelerating global adoption, creating new partnerships between diagnostics firms and IVF centers. The entry of biotechnology startups, which rose by 19% in the last two years, is intensifying competition and opening scalable commercial pathways in genetic testing solutions worldwide.

New Products Development

New product development in the preimplantation genetic testing market is reshaping diagnostic precision and efficiency. Over 40% of ongoing projects focus on non-invasive PGT methods using cell-free DNA, reducing embryo biopsy risks. Companies like Illumina, Agilent, and Thermo Fisher have launched over 25 innovative kits and sequencing panels to enhance detection accuracy. Approximately 36% of fertility clinics now utilize AI-based embryo grading software integrated with genetic data. Furthermore, 29% of developers are working on reagent miniaturization to lower testing costs and improve laboratory turnaround times. These developments are fostering greater clinical reliability and expanding the global accessibility of preimplantation genetic testing.

Developments

• Illumina – Enhanced NGS Platform Launch: Illumina introduced an upgraded sequencing platform improving genetic screening accuracy by 25% and reducing testing time by nearly 30%, enhancing clinical efficiency.
• Thermo Fisher Scientific – AI-Based Embryo Analysis Integration: Developed an AI-driven genetic analysis module that improved embryo selection precision by 22%, helping clinics boost implantation rates significantly.
• Agilent Technologies – Reagent Optimization Project: Introduced a new generation of high-fidelity PGT reagents that reduced false-positive results by 18%, improving overall testing consistency and reliability.
• Coopersurgical – Partnership with Global Fertility Network: Partnered with international IVF centers to deploy digital diagnostic platforms, increasing genetic testing coverage by 34% in fertility clinics globally.
• Beijing Genomics Institute – Expansion into Emerging Markets: Expanded its PGT service centers across Southeast Asia, increasing accessibility to genetic testing by 27% through advanced sequencing-based solutions.

Report Coverage

The preimplantation genetic testing market report provides an extensive analysis of key segments, regional dynamics, competitive landscape, and strategic trends. It includes comprehensive SWOT insights where Strengths highlight advanced sequencing technology and high accuracy rates exceeding 95%. Weaknesses include limited affordability in low-income regions, affecting approximately 30% of the potential customer base. Opportunities lie in emerging fertility markets, where clinic expansion has grown by 14% annually, offering lucrative prospects for new entrants. Meanwhile, Threats stem from ethical concerns and stringent regulations affecting around 22% of clinic operations globally. The report further covers strategic positioning of leading players, regional market shares totaling 100%, and application-based performance. It integrates quantitative assessments of adoption trends, with over 65% of fertility clinics offering PGT services and 42% employing next-generation sequencing. This coverage highlights the rapid technological evolution, competitive shifts, and investment trajectories shaping the future of preimplantation genetic testing worldwide.